Table 1 Survival outcomes

From: Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

 

PFS

OS

 

CT

Bev + CT

CT

Bev + CT

Right side

    

NO16966

    

 N

107

117

107

117

 Median (95% CI)

7.6 (5.9, 9.9)

8.6 (7.6, 10.2)

17.7 (14.7, 21.0)

20.1 (17.5, 23.5)

AVF2107

    

 N

103

103

103

103

 Median (95% CI)

5.4 (4.4, 5.8)

8.7 (8.1, 10.6)

13.6 (10.6, 16.7)

15.9 (12.7, 19.6)

Pooled

    

 N

210

220

210

220

 Median (95% CI)

5.8 (5.4, 7.4)

8.7 (8.2, 10.1)

15.6 (13.6, 17.9)

18.3 (16.0, 20.6)

 HR (95% CI)

 p value

0.75 (0.61, 0.93)

0.008

0.82 (0.65, 1.03)

0.085

Left side

    

NO16966

    

 N

386

380

386

380

 Median (95% CI)

8.5 (8.0, 9.0)

9.6 (9.2, 10.2)

22.4 (20.5, 24.6)

23.3 (21.2, 24.8)

AVF2107

    

 N

199

195

199

195

 Median (95% CI)

7.8 (5.7, 8.2)

11.0 (10.2, 13.0)

16.4 (15.3, 19.6)

24.2 (19.9, NR)

Pooled

    

 N

585

575

585

575

 Median (95% CI)

8.2 (7.9, 8.5)

10.0 (9.4, 10.8)

20.8 (19.6, 22.4)

23.5 (21.6, 24.8)

 HR (95% CI)

 p value

0.76 (0.67, 0.86)

<0.001

0.85 (0.74, 0.98)

0.028

  1. Bev bevacizumab, CI confidence interval, CT chemotherapy, HR hazard ratio, PFS progression-free survival, OS overall survival
Back to article page